ALLOGENE THERAPEUTICS INC
NASDAQ: ALLO (Allogene Therapeutics, Inc.)
Last update: yesterday, 11:03PM2.26
-0.15 (-6.22%)
| Previous Close | 2.41 |
| Open | 2.39 |
| Volume | 6,274,396 |
| Avg. Volume (3M) | 5,621,983 |
| Market Cap | 550,938,112 |
| Price / Sales | 7.78 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 23.07% |
| Current Ratio (MRQ) | 9.71 |
| Operating Cash Flow (TTM) | -197.33 M |
| Levered Free Cash Flow (TTM) | -96.65 M |
| Return on Assets (TTM) | -28.92% |
| Return on Equity (TTM) | -59.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Allogene Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 17.70% |
| % Held by Institutions | 81.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Patient Square Capital Lp | 31 Dec 2025 | 4,963,756 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (UBS, 253.98%) | Buy |
| Median | 6.50 (187.61%) | |
| Low | 5.00 (Citizens, 121.24%) | Buy |
| Average | 6.50 (187.61%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 09 Jan 2026 | 5.00 (121.24%) | Buy | 1.71 |
| UBS | 07 Jan 2026 | 8.00 (253.98%) | Buy | 1.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BENESKI BENJAMIN MACHINAS | - | 2.44 | -4,835 | -11,797 |
| CHANG DAVID D | - | 2.44 | -47,763 | -116,542 |
| Aggregate Net Quantity | -52,598 | |||
| Aggregate Net Value ($) | -128,339 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.44 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHANG DAVID D | Officer | 16 Mar 2026 | Sell (-) | 47,763 | 2.44 | 116,542 |
| BENESKI BENJAMIN MACHINAS | Officer | 16 Mar 2026 | Sell (-) | 4,835 | 2.44 | 11,797 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Allogene Therapeutics Announces Participation in Upcoming Investor Conferences |
| 08 Jan 2026 | Announcement | Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |